Loading…
Cardiff Oncology, Inc. is projected to decline to $1.27 by 2027, a -5% move from its current price of $1.33. CRDF is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.28 | $1.33 | $1.39 | -0.03% |
| Jul 13 | $1.25 | $1.33 | $1.41 | -0.05% |
| Jul 14 | $1.24 | $1.33 | $1.43 | -0.08% |
| Jul 15 | $1.22 | $1.33 | $1.44 | -0.10% |
| Jul 16 | $1.21 | $1.33 | $1.46 | -0.13% |
| Jul 17 | $1.20 | $1.33 | $1.47 | -0.16% |
| Jul 18 | $1.19 | $1.33 | $1.48 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.33 | $1.48 | -0.18% |
| Week 2 | $1.13 | $1.33 | $1.55 | -0.37% |
| Week 3 | $1.09 | $1.32 | $1.60 | -0.55% |
| Week 4 | $1.06 | $1.32 | $1.65 | -0.73% |
| Week 5 | $1.03 | $1.32 | $1.69 | -0.91% |
| Week 6 | $1.00 | $1.32 | $1.72 | -1.09% |
| Week 7 | $0.9812 | $1.31 | $1.76 | -1.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company that develops novel therapies for the treatment of various cancers in the United States.
Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. Cardiff Oncology, Inc. was formerly known as Trovagene, Inc.
and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cardiff Oncology, Inc. (CRDF) is trading in healthcare as a biotechnology-focused stock. The current price is $1.25 and the market cap stands at $85.46M, with a rank of 4290.
The price outlook from the year-by-year forecast shows modest near-term activity, with 2026 at an avg of $1.25 and 2027–2028 hovering around $1.18 and $1.13 respectively before rising through 2029. The multi-year forecast turns bullish from 2030 onward, with the 2030 avg price at $1.65 and notable upside through 2050, ending at an avg of $5.41 and a max of $12.10.
A major floor 43.6% below — a decisive break under it would weaken the trend.
The nearest floor, 11.3% below — buyers have tended to step in here.
The nearest ceiling, 42.9% above — a clean break opens room to run.
A major ceiling 64.7% above — clearing it would confirm fresh momentum.
Key CRDF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRDF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.31 | Buy | $1.31 | Buy |
| MA 10 | $1.29 | Buy | $1.30 | Buy |
| MA 20 | $1.31 | Buy | $1.34 | Sell |
| MA 50 | $1.52 | Sell | $1.47 | Sell |
| MA 100 | $1.63 | Sell | $1.65 | Sell |
| MA 200 | $1.97 | Sell | $1.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.86 | Neutral |
| Stoch RSI (14) | 99.15 | Sell |
| CCI (20) | 21.28 | Neutral |
| Williams %R (14) | -14.29 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 6.40 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 85.71 | Sell |
| TRIX (15) | -0.86 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 53.84 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 1.31 | Buy |
| ADX (14) | 15.97 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is neutral. RSI14 is 40, with a SMA50 of $1.54 and a SMA200 of $1.98. Near-term support sits at $1.18 and resistance at $1.94. The 30-day price range is $0.9434 to $1.66.
Annualized volatility sits at 80%, indicating relatively high price fluctuations within the window analyzed.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.18 | $1.33 | $1.55 | 0% | Neutral | |
| $0.9605 | $1.27 | $1.80 | -5% | Neutral | |
| $0.9019 | $1.25 | $1.86 | -6% | Neutral | |
| $1.06 | $1.52 | $2.36 | +14% | Neutral | |
| $1.24 | $1.83 | $2.95 | +38% | Bullish | |
| $1.27 | $1.95 | $3.23 | +47% | Bullish | |
| $1.32 | $2.08 | $3.53 | +56% | Bullish | |
| $1.22 | $1.98 | $3.44 | +49% | Bullish | |
| $1.15 | $1.92 | $3.42 | +44% | Bullish | |
| $1.19 | $2.03 | $3.68 | +53% | Bullish | |
| $1.66 | $3.21 | $6.31 | +141% | Bullish | |
| $2.84 | $6.30 | $13.92 | +374% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.18 | $1.33 | $1.61 | +0.00% |
| August 2026 | $1.07 | $1.29 | $1.59 | -3.33% |
| September 2026 | $1.07 | $1.30 | $1.64 | +1.01% |
| October 2026 | $1.08 | $1.32 | $1.68 | +1.28% |
| November 2026 | $1.01 | $1.24 | $1.61 | -5.42% |
| December 2026 | $0.955 | $1.18 | $1.55 | -4.75% |
Click any year to see its month-by-month CRDF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRDF to range from $1.18 to $1.55 through 2026. The $1.33 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CRDF price prediction for 2027 points to an average of $1.27 (low $0.9605, high $1.80) — a potential decline of -5% on today's $1.33. A consolidation phase looks the most probable path here.
In 2028, CRDF is projected to trade between $0.9019 and $1.86, averaging $1.25 — a potential decline of -6% from today's $1.33. That is -2% versus the projected 2027 average. Price action looks broadly range-bound.
Cardiff Oncology, Inc.'s 2029 outlook centres on $1.52, within a $1.06 to $2.36 range. That is up +22% on the projected 2028 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, CRDF could reach as high as $2.95, with a base case around $1.83 and support toward $1.24 — roughly +38% from $1.33. Momentum favours further upside here.
Expect CRDF to range from $1.27 to $3.23 through 2031. The $1.95 average target implies a +47% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CRDF price prediction for 2032 points to an average of $2.08 (low $1.32, high $3.53) — a potential gain of +56% on today's $1.33. Momentum favours further upside here.
In 2033, CRDF is projected to trade between $1.22 and $3.44, averaging $1.98 — a potential gain of +49% from today's $1.33. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Cardiff Oncology, Inc.'s 2034 outlook centres on $1.92, within a $1.15 to $3.42 range. That is -3% versus the projected 2033 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2035, CRDF could reach as high as $3.68, with a base case around $2.03 and support toward $1.19 — roughly +53% from $1.33. Buyers look set to stay in control over this stretch.
Expect CRDF to range from $1.66 to $6.31 through 2040. The $3.21 average target implies a +141% move from current prices. That is up +58% on the projected 2035 average. Momentum favours further upside here.
The CRDF price prediction for 2050 points to an average of $6.30 (low $2.84, high $13.92) — a potential gain of +374% on today's $1.33. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRDF today (≈ 751.879699 CRDF) could be worth
$4,738.22
+$3,738.22 (+374%) by 2050 · US Dollar
Based on the average projected CRDF price of $6.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRDFwould be worth at today's price.
$1,000 invested in CRDF on Jul 10, 2025 (≈ 240.384624 CRDF) would be worth
$319.71
-$680.29 (-68.0%) today · 0.32× · US Dollar
Based on a CRDF entry price of $4.16 vs. today's $1.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.27 | $1,047.24 | +4.7% |
| 1 month ago | $1.48 | $898.65 | -10.1% |
| 3 months ago | $1.58 | $841.77 | -15.8% |
| 6 months ago | $2.87 | $463.41 | -53.7% |
| 1 year ago | $4.16 | $319.71 | -68.0% |
| All time (5.0y) ago | $6.51 | $204.3 | -79.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRDF forecast.
Our base-case forecast reaches $2.70 around 2040.
Implied market cap at $2.70: $184.6M
The long-range forecast shows a shift from neutral sentiment in the near term to bullish momentum in the longer term. The 2030 forecast lists an avg of $1.65 with a max of $2.68 and a min of $1.11, delivering a 32.2% ROI. The sentiment for 2030 is bullish, with continued bullish momentum through 2035 and into 2040 and 2050, where the avg prices rise to $2.80 (2040) and $5.41 (2050) with ROIs of 124% and 332.7% respectively.
Specifically, the forecast shows 2040 avg $2.80 and 2050 avg $5.41, with maxs of $5.57 (2040) and $12.10 (2050). The 2031–2035 period remains bullish, with avg prices between $1.75 and $1.78 and ROIs from 40.3% to 42.6%. These figures illustrate potential long-term upside but are not guarantees and depend on market conditions and other factors.
Tap a question to reveal the answer.
Avg price $1.65, with a min of $1.11 and a max of $2.68; ROI 32.2%; sentiment BULLISH.
Near-term forecasts show neutral sentiment (2026 avg $1.25; 2027 avg $1.18; 2028 avg $1.13; 2029 avg $1.36; ROIs range from 0% to 8.9%). The outlook becomes bullish from 2030 onward, with higher avg prices and ROIs (e.g., 2030 avg $1.65, ROI 32.2%; 2040 avg $2.80, ROI 124%; 2050 avg $5.41, ROI 332.7%). These are estimates, not guarantees.
The forecast max price by 2050 is $12.10, with an avg of $5.41 and a min of $2.43. This indicates possible appreciation under certain conditions, but is not guaranteed.
Current price is $1.25 and market cap is $85.46M with a rank of 4290.
RSI14 is 40.0; SMA50 is $1.54; SMA200 is $1.98; support is $1.18 and resistance is $1.94. The 30-day range is $0.9434 to $1.66 and annualized volatility is 80%.
Cardiff Oncology, Inc. Community Discussion
0Share your Cardiff Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.